Carbohydrate-based therapeutics

Adamo, Roberto. (Added Author). Lay, Luigi. (Added Author).

Summary: Comprehensive resource summarizing opportunities and latest progress in design methodologies for carbohydrate-based therapeutics through a disease-oriented approach Carbohydrate-Based Therapeutics covers current progress and explores new frontiers in carbohydrate-based therapeutic applications, utilizing a unique approach by providing a detailed background of diseases coupled with subsequent carbohydrate-based therapies. The link between chemistry and design of novel carbohydrate-based medicines is highlighted and a broad overview of all the potential applications of carbohydrates is given. Emphasis is laid on concepts used for carbohydrate drug design, structure- activity relationship, and impact on health and diseases. The text also discusses newer topics like nanoparticles, material science, and tissue generation. Carbohydrate-Based Therapeutics includes information on: Antimicrobial carbohydrate-based therapies, covering antibacterial and antiviral vaccines, antifungal therapies, anti-influenza therapeutics, and antiadhesive carbohydrates and glycomimetics Anti-cancer carbohydrate-based therapies, covering cancer vaccines and immunotherapy, and carbohydrate tools in cancer biology Carbohydrate-based therapies in metabolic, neuronal, and immune disorders, covering carbohydrate-based therapeutics for lysosomal disorders and neurodegenerative diseases New frontiers in carbohydrate-based therapies, covering carbohydrates for tissue engineering, antiangiogenic and regenerative medicine Providing comprehensive coverage of foundational knowledge on the subject in a unique and highly accessible format while also exploring the state of the art in the field's applications, Carbohydrate-Based Therapeutics is an essential resource for medicinal, pharmaceutical, and organic chemists, chemists in industry, biochemists, and biotechnologists.

Record details

ISBN: 9783527348701 (hardcover)
Physical Description: xvii, 390 pages : illustrations (some color) ; 26 cm
print
Publisher: Weinheim : Wiley-VCH, [2024].
Copyright: ©2024

Content descriptions

Bibliography, etc. Note:

Includes bibliographical references and index.

Formatted Contents Note:

Introduction -- DC-SIGN Ligands Employing Natural Carbohydrate Epitopes -- Dendrimers -- Nanoparticles -- Polymers -- Other Multivalent Scaffolds -- DC-SIGN Ligands Employing Carbohydrate Derivatives or Glycomimetics -- Conclusion and Perspectives -- The Bacterial Adhesin FimH -- UTIs and FimH -- FimH CRD -- FimH Antagonists -- Conclusion and Perspectives -- Pseudomonas aeruginosa Virulence Factors (PA-IL and PA-IIL) -- Introduction -- Mono- and Oligovalent Glycomimetic PL-Ligands -- Conclusions and Perspectives -- General Aspects -- References -- Targeting Carbohydrates in Cancer - Analytical and Biotechnological Tools -- Aberrant Protein Glycosylation in Cancer -- Detection and Mapping of Carbohydrate-Based Antigens in Human Neoplastic Tissues -- Imaging Mass Spectrometry -- In Situ Proximity Ligation Assay -- Glycan Microarrays -- Glycoengineered In Vitro, In Vivo, and Ex Vivo Models -- Structural Elucidation of Glycoconjugates: Glycomic and Glycoproteomic Strategies -- Concluding Remarks -- List of Abbreviations -- References -- Carbohydrate-Specific Monoclonal Antibody Therapeutics -- Introduction -- Types of Monoclonal Antibodies -- IgG Antibodies -- IgM Antibodies -- ScFv and Fab Fragments -- Humanization of Monoclonal Antibodies -- CDR Grafting -- Transgenic Animals -- Breakthrough Research -- mAbs from Preclinical to Clinical Studies -- Globo Series -- Blood Group -- Mucin-Attached Glycans -- New Treatment Options for Neuroblastoma -- History of Unituxin -- What is Unituxin? -- Challenges with Unituxin -- A mAbs Binding to Neuroblastoma -- Chimeric and Humanized Anti-GD2 Antibodies -- Naxitamab as a Potential Alternative for High-Risk Patients -- Chimeric Antigen Receptors (CARs) Targeting GD2 -- Summary -- List of Abbreviations -- References -- Carbohydrates in Tissue Engineering -- Introduction -- Biomaterials and Medical Devices: Natural and Synthetic Strategies -- Carbohydrates as Building Blocks for Medical Device Formulation -- Human Polysaccharides: Glycosaminoglycans (GAGs) and Proteoglycans (PGs) -- Polysaccharides from Plants, Algae, Animal, and Microbial Fermentation -- Carbohydrates as Signaling Molecules: Opportunities in Tissue Engineering and Regenerative Medicine -- Carbohydrates in Animal-Derived Medical Devices: Friends or Foes? -- Glycoengineering Application to Regenerative Medicine -- Future Opportunities and Major Challenges -- Conflict of Interest -- References -- Carbohydrate-Based Therapeutics for Lysosomal Storage Disorders -- An Introduction to Lysosomal Storage Disorders (LSDs) -- Available Treatments for LSDs: The Role of Carbohydrate-Based Therapeutics -- Enzyme Replacement Therapy (ERT) -- Substrate Reduction Therapy (SRT) -- Pharmacological Chaperone Therapy (PCT) -- Combined ERT/PC Therapy -- Mucopolysaccharidoses -- Sphingolipidoses -- Fabry Disease -- Gaucher Disease -- Niemann-Pick -- GM1 Gangliosidosis and Morquio B (β-Gal) -- GM2 Gangliosidosis (β-Hexosaminidase) -- Krabbe -- Glycogen Storage Disorders -- Pompe Disease -- Glycoproteinoses -- Fucosidosis -- α-Mannosidosis -- Conclusions -- Acknowledgments -- Abbreviations and Acronyms -- References -- Carbohydrates and Carbohydrate-Based Therapeutics in Alzheimer's Disease -- Introduction -- O-GlcNAc Transferase (OGT) and O-GlcNAc Hydrolase (OGA) in Neurodegeneration -- O-GlcNAc Cycling as a Therapeutic Target Against Alzheimer's Amyloid Plaques and Neurofibrillary Tangles -- OGA Inhibitors -- PUGNAc -- GlcN Acstatins -- Thiazoline Inhibitors -- GalNAc in Neurodegeneration -- Chitosan and Derivatives in AD Brain -- Cholinesterase Inhibitors -- Fyn Kinase Inhibitors -- Amyloid Protein-Protein Interaction Inhibitors -- Inhibitors of Aβo and/or Oxidative Stress-Induced Neurotoxicity -- Carbohydrate-Protein Interactions as Potential Therapeutic Targets Against AD -- Lipid-Raft Gangliosides as Membrane Accumulation Sites for Toxic Aβ Aggregates -- The Role of Microglial Cells in Aβ Brain Clearance -- Conclusion -- List of Abbrev iations -- Acknowledgments -- References -- Carbohydrate-Based Antithrombotics -- Introduction -- Antithrombotic Drugs -- Heparin -- Mechanism of Interaction with Coagulation Factors -- Antithrombin-Mediated Activity -- Heparin Cofactor II Mediated Activity -- Additional Factors -- Adverse Effects of Heparin -- Heparin-Induced Thrombocytopenia -- Osteoporosis -- Low Molecular Weight Heparins -- Ultralow Molecular Weight Heparins -- Drugs Based on Natural GAG Mixtures -- The Role of Dermatan Sulfate -- Sulodexide -- Danaparoid -- Mesoglycan -- Defibrotide -- Pentosan Polysulfate -- Fondaparinux and Related Synthetic Oligosaccharides -- Chemoenzymatic Synthesis of Oligosaccharides -- Conclusions and Perspectives -- Acknowledgment -- References -- Index.